135 related articles for article (PubMed ID: 35429966)
21. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.
Thompson T; Andreeff M; Studzinski GP; Vassilev LT
Mol Cancer Ther; 2010 May; 9(5):1158-68. PubMed ID: 20406950
[TBL] [Abstract][Full Text] [Related]
22. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Saha MN; Jiang H; Chang H
Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
[TBL] [Abstract][Full Text] [Related]
24. Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.
Trino S; Iacobucci I; Erriquez D; Laurenzana I; De Luca L; Ferrari A; Ghelli Luserna Di Rorà A; Papayannidis C; Derenzini E; Simonetti G; Lonetti A; Venturi C; Cattina F; Ottaviani E; Abbenante MC; Russo D; Perini G; Musto P; Martinelli G
Oncotarget; 2016 Mar; 7(11):12951-61. PubMed ID: 26887044
[TBL] [Abstract][Full Text] [Related]
25. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
[TBL] [Abstract][Full Text] [Related]
26. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
McCormack E; Haaland I; Venås G; Forthun RB; Huseby S; Gausdal G; Knappskog S; Micklem DR; Lorens JB; Bruserud O; Gjertsen BT
Leukemia; 2012 May; 26(5):910-7. PubMed ID: 22064349
[TBL] [Abstract][Full Text] [Related]
27. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
Tseng HY; Jiang CC; Croft A; Tay KH; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Mol Cancer Ther; 2010 Dec; 9(12):3363-74. PubMed ID: 21159614
[TBL] [Abstract][Full Text] [Related]
28. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.
Villalonga-Planells R; Coll-Mulet L; Martínez-Soler F; Castaño E; Acebes JJ; Giménez-Bonafé P; Gil J; Tortosa A
PLoS One; 2011 Apr; 6(4):e18588. PubMed ID: 21483692
[TBL] [Abstract][Full Text] [Related]
29. MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation.
Borthakur G; Duvvuri S; Ruvolo V; Tripathi DN; Piya S; Burks J; Jacamo R; Kojima K; Ruvolo P; Fueyo-Margareto J; Konopleva M; Andreeff M
PLoS One; 2015; 10(10):e0139254. PubMed ID: 26440941
[TBL] [Abstract][Full Text] [Related]
30. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
31. TRIAD1 Is a Novel Transcriptional Target of p53 and Regulates Nutlin-3a-Induced Cell Death.
Lee J; An S; Choi YM; Jung JH; Li L; Meng H; Dong Y; Ahn KJ; An IS; Bae S
J Cell Biochem; 2017 Jul; 118(7):1733-1740. PubMed ID: 27935098
[TBL] [Abstract][Full Text] [Related]
32. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
[TBL] [Abstract][Full Text] [Related]
33. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.
Gu L; Zhu N; Findley HW; Zhou M
Leukemia; 2008 Apr; 22(4):730-9. PubMed ID: 18273046
[TBL] [Abstract][Full Text] [Related]
34. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
[TBL] [Abstract][Full Text] [Related]
35. Triptolide induces apoptosis of gastric cancer cells via inhibiting the overexpression of MDM2.
Wang BY; Cao J; Chen JW; Liu QY
Med Oncol; 2014 Nov; 31(11):270. PubMed ID: 25280518
[TBL] [Abstract][Full Text] [Related]
36. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells.
Zhu N; Gu L; Li F; Zhou M
Mol Cancer Ther; 2008 May; 7(5):1101-9. PubMed ID: 18483299
[TBL] [Abstract][Full Text] [Related]
38. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
Ohnstad HO; Paulsen EB; Noordhuis P; Berg M; Lothe RA; Vassilev LT; Myklebost O
BMC Cancer; 2011 May; 11():211:1-11. PubMed ID: 21624110
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors.
Briest F; Grass I; Sedding D; Möbs M; Christen F; Benecke J; Fuchs K; Mende S; Kaemmerer D; Sänger J; Kunze A; Geisler C; Freitag H; Lewens F; Worpenberg L; Iwaszkiewicz S; Siegmund B; Walther W; Hummel M; Grabowski P
Neuroendocrinology; 2018; 107(1):1-23. PubMed ID: 28910819
[TBL] [Abstract][Full Text] [Related]
40. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
